Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.Chronic kidney disease is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. It has emerged as a global epidemic and growing problem that places an enormous social and economic burden on patients, their families, and society.Advances in kidney transplantation and dialysis over half a century ago extended life for patients with kidney failure, yet the current standard of care for patients with kidney disease remains inadequate, and there is an urgent need for new treatment options.Recent breakthroughs in genetics and biology have generated an unparalleled understanding of the biological pathways that drive kidney disease. Goldfinch is uniquely positioned to translate these discoveries into new therapies that target the molecular causes of kidney disease.
|HQ||Cambridge, MA, US||Map|
Goldfinch Bio total Funding
Goldfinch Bio latest funding size
Time since last funding
|7 months ago|
Goldfinch Bio investors
|BlackRock, Ally Bridge Group, Casdin Capital, Gilead Sciences, Eventide Asset Management, Yonjin Capital, Wellington Management Company, Schroeder Adveq|
Who are Goldfinch Bio key executives?
Goldfinch Bio's key executives are Anthony Johnson, Frank S. Czerwiec and Peter Mundel.
Who are Goldfinch Bio competitors?
Competitors of Goldfinch Bio include LGC, Principia BioPharma and Verona Pharma.
Where is Goldfinch Bio headquarters?
Goldfinch Bio headquarters is located at 215 First St 4th floor, Cambridge.
Where are Goldfinch Bio offices?
Goldfinch Bio has an office in Cambridge.
How many offices does Goldfinch Bio have?
Goldfinch Bio has 1 office.
Receive alerts for 300+ data fields across thousands of companies